Clinical Trials Browser

Phase 2 × Small Cell Lung Carcinoma × tislelizumab × Clear all

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06536868 2024-08-05

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06375109 2024-04-19

NeoSCLC-001

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04542369 2023-05-03

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2 Unknown

Small Cell Lung Carcinoma